BPHC Bulletin: CDC and FDA Call for Pause on Administration of J&J Vaccine

bphc health center program bulletin

This morning, HHS released a Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine. Based on six reported cases of a rare and severe type of blood clot, HHS recommends that vaccine providers pause on administering the Johnson & Johnson (J&J) COVID-19 vaccine.

CDC’s Advisory Committee on Immunization Practices (ACIP) is meeting on Wednesday and will provide updates. CDC and FDA will provide additional information and answer questions later today at a media briefing. A recording of that media call will be available on the FDA’s YouTube channel.

People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System.